Kezar Life Sciences Inc (NASDAQ:KZR) Expected to Post Earnings of -$0.21 Per Share

Equities analysts expect Kezar Life Sciences Inc (NASDAQ:KZR) to report earnings per share of ($0.21) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Kezar Life Sciences’ earnings, with the lowest EPS estimate coming in at ($0.22) and the highest estimate coming in at ($0.19). Kezar Life Sciences posted earnings per share of ($0.48) during the same quarter last year, which would indicate a positive year over year growth rate of 56.3%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, November 4th.

According to Zacks, analysts expect that Kezar Life Sciences will report full-year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($0.95) to ($0.90). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.06) to ($0.95). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Kezar Life Sciences.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.04.

Several research firms have commented on KZR. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Kezar Life Sciences in a research note on Tuesday, September 22nd. Zacks Investment Research downgraded shares of Kezar Life Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, October 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Kezar Life Sciences presently has a consensus rating of “Hold” and a consensus price target of $11.83.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bellevue Group AG boosted its position in Kezar Life Sciences by 20.5% during the second quarter. Bellevue Group AG now owns 4,241,940 shares of the company’s stock worth $21,973,000 after purchasing an additional 723,051 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Kezar Life Sciences by 176.5% during the 1st quarter. Victory Capital Management Inc. now owns 1,370,027 shares of the company’s stock worth $5,973,000 after acquiring an additional 874,576 shares in the last quarter. Cormorant Asset Management LP bought a new position in shares of Kezar Life Sciences in the 2nd quarter valued at approximately $6,734,000. Candriam Luxembourg S.C.A. acquired a new stake in Kezar Life Sciences in the 2nd quarter worth approximately $3,108,000. Finally, Alyeska Investment Group L.P. boosted its position in Kezar Life Sciences by 140.1% during the second quarter. Alyeska Investment Group L.P. now owns 588,502 shares of the company’s stock worth $3,048,000 after purchasing an additional 343,383 shares during the period. 50.15% of the stock is currently owned by institutional investors.

Kezar Life Sciences stock traded up $0.34 during mid-day trading on Friday, reaching $5.63. 194,776 shares of the company’s stock traded hands, compared to its average volume of 442,974. The stock has a 50 day moving average of $4.87 and a two-hundred day moving average of $4.94. Kezar Life Sciences has a 12-month low of $2.18 and a 12-month high of $9.79. The company has a market cap of $260.42 million, a price-to-earnings ratio of -3.75 and a beta of 0.12.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Featured Article: Portfolio Manager

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kezar Life Sciences (NASDAQ:KZR)

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.